Immunotherapy of Head and Neck Cancer: Current and Future Considerations
Patients with head and neck squamous cell carcinoma (HNSCC) are at considerable risk for death, with 5-year relative survival rates of approximately 60%. The profound multifaceted deficiencies in cell-mediated immunity that persist in most patients after treatment may be related to the high rates of...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Hindawi Publishing Corporation
2009
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723756/ |